Alves, C L, Ehmsen, S, Terp, M G, Portman, N, Tuttolomondo, M, Gammelgaard, O L, Hundebøl, M F, Kaminska, K, Johansen, L E, Bak, M, Honeth, G, Bosch, A, Lim, E & Ditzel, H J 2021, ' Publisher Correction : Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9) ', Nature Communications, vol. 12, 5588 . https://doi.org/10.1038/s41467-021-25901-z
Karimi, L, Alves, C L, Terp, M G, Tuttolomondo, M & Ditzel, H J 2021, ' Triple combination targeting ER, CDK4/6, and PI3K inhibits tumor growth in ER plus breast cancer resistant to combined fulvestrant and CDK4/6 or PI3K inhibitor ', Cancer research, vol. 81, no. Suppl. 13, 1415 . https://doi.org/10.1158/1538-7445.AM2021-1415